Initial Antireflux Regimen for Suspected Eosinophilic Esophagitis

Rationale for PPI as First-Line Therapy

The American Gastroenterological Association recognizes PPIs as a legitimate treatment for esophageal eosinophilia, rather than merely a diagnostic exclusion criterion, as acknowledged by the 2018 international consensus 1, 2
The 2018 international consensus removed the requirement to distinguish "PPI-responsive esophageal eosinophilia" from "true EoE," acknowledging these conditions are clinically, endoscopically, histologically, and molecularly indistinguishable 2, 3

PPIs have anti-inflammatory effects, inhibiting Th2 cytokine-stimulated eotaxin-3 secretion by blocking STAT6 binding to the eotaxin-3 promoter, directly targeting the allergic inflammatory pathway 3
PPIs restore impaired esophageal mucosal barrier function and improve desmoglein-1 expression, similar to topical steroid effects 3
PPIs modulate gene expression, reducing expression of genes related to allergic inflammation, eotaxin-3, IL-5, and mast cell density 3

The American Academy of Pediatrics recommends that all children with typical GERD symptoms refractory to PPI treatment should undergo endoscopy to exclude eosinophilic esophagitis 1, 4

The American Gastroenterological Association defines remission as <15 eosinophils per 0.3 mm² (high-power field), requiring a minimum of 6 biopsies from different esophageal sites 1, 4

The American College of Gastroenterology acknowledges that eosinophilic esophagitis and GERD are not mutually exclusive and frequently coexist in the same patient, supporting the use of PPIs regardless of whether the primary mechanism is acid-mediated or allergen-driven 1, 4
The European Society for Pediatric Gastroenterology, Hepatology, and Nutrition supports using PPIs as the initial approach, given the substantial response rate and excellent safety profile 3

The American Gastroenterological Association recommends a standard dose of 20-40 mg twice daily for 8-12 weeks in adults 5, 6, 7
In children, the recommended dose is 1 mg/kg per dose, twice daily for 8-12 weeks, with a maximum dose based on adult recommendations 5, 7
Proton pump inhibitors should be taken 30-60 minutes before meals for optimal efficacy, as recommended by medical guidelines 8

An endoscopy with biopsies under treatment is mandatory after 8-12 weeks to evaluate histological response, as symptoms do not always correlate with histological activity, according to the European Society of Gastrointestinal Endoscopy 6
Histological remission is defined as <15 eosinophils per high-power field, as stated by the American Academy of Allergy, Asthma, and Immunology 5, 6

Patients in remission should continue proton pump inhibitor treatment to maintain remission, as recommended by the European Society of Gastrointestinal Endoscopy 6, 9
A control endoscopy is recommended if symptoms recur under treatment, according to the American Gastroenterological Association 6

A minimum of 8 weeks of treatment is necessary, as shorter durations may be insufficient to observe a complete response, as stated by the European Society of Gastrointestinal Endoscopy 10
Failure to respond to proton pump inhibitors is compatible with a diagnosis of true eosinophilic esophagitis, according to the American Academy of Allergy, Asthma, and Immunology 5, 7
Endoscopy with biopsies under treatment is essential to evaluate histological response, as recommended by the European Society of Gastrointestinal Endoscopy 6